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Dopamine acts as neurotransmitter in the central and peripheral sympathetic nervous system. Determination of dopamine (DO)
was performed by spectrophotometric analysis depending on the formation of new colored compound. The proposed procedure
was eﬃcient in quantitative determination of DO as pure material in pharmaceutical preparations and in urine samples. DO
concentration in urine sample of patient conﬁrms the aﬀection with schizophrenia and the proposed procedure was used to
facilitatediagnosisandfollowupofschizophrenicpatients.Itisrecommendedtoapplytheproposedproceduresasroutineanalysis
in pharmaceutical companies for quality control and in analytical laboratories to diagnose and follow up schizophrenia.
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1. INTRODUCTION
Dopamine and dopamine derivatives were a group of bio-
genic amines possessing a 3,4-dihydroxy substituted phenyl
ring (Figure 1). They are considered as a type of hormones
widely spread in animals and had also been detected in 44
plant families [1, 2]. They also seemed to be a central phar-
macophore and well probably existed in future drugs, espe-
cially in those developed for psychiatry disorders and neu-
rological activity [3]. It was not until the late 1950s that
dopamine was recognized as a mammalian neurotransmit-
ter in its own right but the demonstration of its nonuniform
distribution inthebrainsuggestedthatitmighthasaspeciﬁc
functional role for dopamine [4]. It had therapeutic uses as
a cardiostimulant and had important role in the pathogene-
sis or drug treatment of certain brain diseases, for example,
Parkinson’s disease and schizophrenia [5].
Several methods were applied on pharmaceutical prepa-
rations containing DO.HCl or LD depending on oxidation
reaction [6–8]. Determination of certain catechol derivatives
like pyrocatechol, DO.HCl, and LD in either pure form or
initspharmaceuticalformulationwassuggestedspectropho-
tometrically [9–11] and indirect kinetic spectrophotometry
[12].
HPLC technique is most predominantly used for screen-
ing of many clinical diagnosis [13–15] and to ﬁnd the
diﬀerence between the measured and ordered doses of
catecholamine infusion [16]. Flow injection analysis (FIA)
systemusingtubularelectrodewasusedinthedetermination
of DO in pharmaceutical preparations. The process based on
redox properties of copper (II) ions immobilized in a poly
(ethylene-co-vinyl acetate) (EVA) membrane and oxidation
of DO [17].
In continuation to our interest in microdetermination
of these drugs under study [18], the aim of the present
work is to describe the development of simple, sensitive,
and rapid spectrophotometric method for the determination
of DO.HCl depending on the formation of coloured com-
plex between DO and copper sulfate and 4-amonoantipyrine
(4-AAP). Diﬀerent experimental conditions are carefully
studied before applying Beer’s law. The method was ap-
plied for determining DO in urine samples collected from
schizophrenic patients and pharmaceutical forms. The re-
sults obtained are of interest and are compared with these
obtained by the oﬃcial method.
2. EXPERIMENTAL
2.1. Procedure
An aliquot containing 74.4–417.2ppm of DO.HCl was trans-
ferred to 10mL measuring ﬂask, followed by adding 4-AAP
and copper sulfate. The pH was adjusted at 10-11. The to-
tal volume was completed up to 10mL. The mixtures were2 Journal of Automated Methods and Management in Chemistry
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Figure 1: Structural formulae of the investigated dopamines.
shacked well and allowed to stand at room temperature.
The pH was rechecked and the absorbance was measured at
480nm for DO.HCl against deionized water as a blank. The
calibration curve was obtained applying the same procedure
using standard solutions of active ingredient.
2.2. Analysisofdosageform
DO.HCl ampoule was incubated in cold, dark bottle and
awayfromoxygenairtopreventoxidationordecomposition.
2.3. AnalysisofDOinurinesamplesofhealthy
individualsandschizophrenicpatients
Urine samples were allowed to stand at room temperature
beforepipetting.Tobesureofcompletehomogeneity,arapid
vortex must be done for 30 seconds.
Certain volume from urine sample was mixed with 4-
AAP and copper sulfate at pH 10-11. The total volume was
completed up to 10mL measuring ﬂask using deionized wa-
ter. The method was completed under optimum conditions.
From the calibration curve, the concentration of dopam-
ine in diﬀerent urine samples can be calculated.
2.4. Resultsanddiscussion
4-AAP reacts with phenolic-type compounds according to
the reaction shows in Figure 2.T h er e a c t i o np r o d u c tm a yb e
of any color from red to purple depending on the phenolic-
type compounds involved [19–21].
Optimum conditions aﬀecting the reaction of DO.HCl
withcoppersulfateand4-AAPwerestudiedcarefully.Theef-
fect of pH was studied in the pH ranging from 9 to 12 and it
was obvious that the most suitable pH is 10-11 for microde-
termination of DO.HCl at λmax = 480nm.
Applying the molar ratio method, it was found that
DO.HCl interacts with 4-AAP and copper sulfate to form
product in ratio 2 : 2 : 1 as [DO] : [4-AAP] : [Cu+2]. The
solidofthisreactionisseparatedandcharacterizedusingdif-
ferent tools like elemental analysis, IR, magnetic and thermal
analysis. By following the reaction at diﬀerent time intervals,
it is obvious that the suitable time needed for complete reac-
tion was 10–30 minutes which was attained at room temper-
ature.
Under the optimum conditions, a correlation was ob-
tained between absorbance (A) and the concentration (C)
over the range at 74.4–417.2μgm L
￿1 of DO.HCl (as shown
in Figure 3). The apparent molar absorptivity, Sandell sensi-
tivity, standard deviation (SD), and coeﬃcient of variation
(CV) for each active ingredient were tabulated in Table 1.
The apparent molar absorpitivity (ε) of the resulting col-
ored products was found to be 2.979
￿104L
￿ mol
￿1
￿ cm
￿1,
whereas Sandell sensitivities were 3
￿10
￿3 μgc m
￿2.T h ec o r -
relation coeﬃcient was found to be 0.999, while the SD
was 0.06–0.3. The low values of CV and SD indicated the
high accuracy, precision, and reproducibility of the proposed
method to determine DO.HCl.
2.5. Interference
Several pharmaceutical preparations were associated with
ﬂavoringagents,diluents,andexcipients.Thecommontoler-
ances, which were examined in our proposed procedure with
active ingredients DO.HCl, were glucose, acetone ascorbic
acid, urea catechol, phenol, pyrogallol, resorcinol, and hy-
droquinone as shown in Table 2.
3. APPLICATIONS
3.1. DeterminationofDO.HClinpharmaceuticalforms
Ourproposedprocedurewasappliedonampoulecontaining
DO.HCl as active ingredient, as shown in Table 3.D e t e c t i o n
of DO.HCl concentration in aliquot solutions was applied
with percent error 0.3%. The percent error was very small
that could be neglected and was in acceptable range of error
for pharmaceutical determination [22, 23].
The calculated values of t and F tests [24] under con-
ﬁdence limit 95% = 2.5–2.8a n d5 .11–5.8, respectively, in-
dicated insigniﬁcant diﬀerence between the oﬃcial [25]a n d
proposed methods and also referred to the robustness of the
proposed procedure.
3.2. DeterminationofDOinurinesamples
ofschizophrenicpatients
Before our method, schizophrenia was diagnosed by physi-
cians clinically through an interview with the patient and
followed-up schizophrenic patients via clinical diagnosis.
Proper response and improvement appear clinically within
4–6 weeks from starting antipsychotic drugs [26].
In the treatment of schizophrenia, more than in many
other diseases, individual patients respond diﬀerently to
medication. Despite recent advances in the treatment of
schizophrenia, there remains a number of unmet needs in
therapy for schizophrenia management like low response,
high relapse rates [27–30], nonresponse [27, 30–37], nonad-
herence [27, 29] or challenging road ahead.
Nowadays with our new option, analytical test is ordered
after a psychiatrist performing his clinical examination [38]
on the patient and suspecting that patient has schizophrenic
symptoms [39]. Actually it can be used as a monitoring tool
to follow up a patient treatment and in conﬁrming psychia-
trist ﬁndings. In addition, it can be applied before treatment,Faten A. Nour El-Dien et al. 3
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Figure 2: Coupling reaction between phenyl and 4-AAP.
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Figure 3: Calibration curve of DO with copper sulfate and 4-AAP.
afterﬁfteendaysfromstartingtreatmentandafterthirtydays
from treatment. By this way, a psychiatrist will have facilities
toevaluatetheschizophrenicpatientasawholeandtofollow
up the responsibility of the patient to recommended treat-
ment according to the DO concentration present in urine
sample. Moreover, it can be ordered as a routine analysis
for early detection when a patient has a family history of
schizophrenia.
3.3. Modiﬁcationinspectrophotometric
determinationofDOinurinesamples
The modiﬁcation is based on formation of colored stripe
sheet, which was picked from the calibration curve of
DO.HCl with copper sulfate and 4-AAP under optimum
conditions. The collected urine sample was mixed with cop-
per sulfate and 4-AAP and allowed to stand under optimum
conditions till complete complex formation, then the end
colored product was compared with colors present in col-
ored stripe sheet. By this way, we will have ability to detect
the concentration of DO in the urine sample easily without
the need to record absorbance at a certain wavelength using
spectrophotometer.
So we can conclude that modiﬁcation in our procedure
facilitates quantitation of DO in urine sample without need
to form calibration curve from time to time using standard
DO material.
Table 1: Diﬀerent analytical parameters for the determination of
DO.HCl, using copper sulfate and 4-AAP.
Parameters DO.HCl
Detection range (mg/L) 74.4–417.2
Correlation coeﬃcient 0.999
Molar absorbitivity (L
￿ mol
￿1
￿ cm
￿1) 2.979
￿104
SD 0.06–0.3
CV (%) 0.1–0.12
Sandell sensitivity 3
￿10
￿3
Table 2: Eﬀect of diﬀerent tolerants on the determination of
DO.HCl using copper sulfate and 4-AAP.
Tolerant Fold Recovery %
— — 100.0
Glucose 10 100.7
Acetone 10 99.30
Ascorbic acid
10 —
1 104.1
0.5 102.6
Urea
10 97.85
1 98.90
0.5 99.60
Catechol 10 370.8
0.5 186.7
Phenol 10 808.8
0.5 189.3
Pyrogallol
10 138.7
1 113.7
0.5 107.4
Resorcinol
10 374.9
1 93.40
0.5 95.94
Hydroquinone
10 239.8
1 161.6
0.5 136.5
4. CONCLUSION
The proposed method and its modiﬁcation for DO estima-
tion were advantageous over many reported methods, where
they facilitate quantitation of DO in urine samples without
the need to form calibration curve from time to time us-
ing standard DO material. Moreover, early detection, diag-
nosis, followsups and prevention of relapse of schizophrenic
patients will be fast and easy.
This method could be used for the routine quality con-
trol analysis due to its sensitivity, rapidity, noninterference4 Journal of Automated Methods and Management in Chemistry
Table 3: Determination of DO.HCl in pharmaceutical preparation using copper sulfate and 4-AAP reagents.
Drug Name of preparation Drug, (ppm) Recovery % SD
￿t test F test
Taken Found PM OM PM OM
DO.HCI
Dopamine Fresenius 76.61 77.34 100.9 100.8 0.10 0.21 1.18 4.41
153.23 153.58 100.2 99.17 0.11 0.25 1.05 5.16
Dopamine Pierre Faba 76.61 78.05 101.8 102.2 0.17 0.20 1.1 1.38
153.23 153.58 100.2 101.1 0.13 0.17 1.5 1.71
￿t test shows the values for V as degree of freedom for 95% conﬁdence level (number of replicates v1 = 5).
￿F test shows the values for V as degree of freedom for variation conﬁdence level (number of replicates v1,, v2 = 5, 3).
with other ingredients usually present in pharmaceutical
preparations, precision,andgoodagreementwiththeoﬃcial
method.
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